Azitra, Inc. (AZTR) Q1 2025 Filing Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing novel therapeutics for precision dermatology using genetically engineered microbes. The company operates as a single segment and is currently in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,068,345) | $(2,932,875) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(4.32) |
| Cash and Cash Equivalents (End of Period) | $3,206,710 | $3,001,158 |
| Working Capital | $2,591,133 | $3,852,433 |
| Total Assets | $5,907,891 | $7,358,802 |
| Total Liabilities | $1,500,267 | $1,660,504 |
| Accumulated Deficit | $(60,634,170) | $(51,531,208) |
Operating Expenses: Total operating expenses were $3.1 million, comprised of $1.85 million in General and Administrative (G&A) costs and $1.25 million in Research and Development (R&D).
Cash Flow: Net cash used in operating activities was $3.07 million. Net cash provided by financing activities was $1.75 million, primarily from follow-on public offerings in January and February 2025.
Material Changes vs. Prior Period
- Net Loss: Increased by approximately 5% ($135,470) compared to Q1 2024, driven by higher G&A expenses.
- G&A Expenses: Increased 24% to $1.85 million due to higher accounting fees, legal fees, public relations, and consultant costs.
- R&D Expenses: Decreased 15% to $1.25 million, primarily due to reduced Chemistry, Manufacturing, and Controls (CMC) costs and consultant fees, partially offset by increased clinical costs for the ATR-04 program.
- Other Income: Interest income increased significantly to $37,164 from $7,609. The gain from the change in fair value of warrants decreased to $143 from $28,255 in the prior year.
- Capital Structure: The company completed two follow-on offerings in Q1 2025 (January and February), raising approximately $1.75 million in net proceeds. Outstanding common shares increased from 7.6 million to 15.0 million during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date. The company has an accumulated deficit of $60.6 million and expects to incur additional losses. It will require significant additional funding to complete product development.
- Financing Needs: The company plans to raise funds through equity and/or debt financing. There is no assurance that such financing will be available on commercially reasonable terms.
- Clinical Pipeline:
- ATR-12: Phase 1b trial for Netherton syndrome; first patient dosed in August 2024. Initial safety results expected in H1 2025.
- ATR-04: Phase 1/2 trial for EGFRi-associated rash; Fast Track designation received. First patient dosing expected in H1 2025.
- ATR-01: Lead optimization and IND-enabling studies planned for 2025 to support an IND filing in early 2026.
- Stock Split: Stockholders approved a potential reverse split (ratio 1:2 to 1:7) in February 2025 to maintain NYSE American compliance. The Board is still evaluating the exact ratio and timing.
- Internal Controls: Management identified a material weakness in disclosure controls and procedures related to a lack of adequate segregation of accounting functions.
- Subsequent Events: On April 24, 2025, the company entered into a Purchase Agreement with Alumni Capital LP for up to $20 million in equity. Initial purchases totaling approximately $401,000 in gross proceeds were made in May 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.2 million cash balance against the projected burn rate of ~$3.1 million per quarter.
- Financing Execution: Monitor the execution of the $20 million Purchase Agreement with Alumni Capital LP and the status of the potential reverse stock split.
- Clinical Milestones: Track the timing of initial safety data readouts for ATR-12 and ATR-04, expected in the first half of 2025.
- Internal Controls: Assess the remediation plan for the material weakness in segregation of accounting duties.
- Dilution Risk: Review the impact of recent and potential future equity issuances on existing shareholder ownership.